Compare KraneShares Hang Seng TECH Index ETF (KTEC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares Hang Seng TECH Index ETF vs Sanofi SA — how do they compare? KraneShares Hang Seng TECH Index ETF trades at $11.81 (market cap $45.04M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 2113.2× KraneShares Hang Seng TECH Index ETF's market cap, and Sanofi SA pays a 6.01% dividend while KraneShares Hang Seng TECH Index ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Hang Seng TECH Index ETF for 44 Days and Sanofi SA for 94 Days on average.
| KTEC | SNY | |
|---|---|---|
Market Cap | $45.04M | $95.18B |
Volume | 29,043 | 2,995,646 |
Sector | Sector/Thematic | Health |
52-Week High | $18.73 | $52.34 |
52-Week Low | $11.41 | $39.51 |
Typical Hold Time | 44 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KTEC trades at $11.81, up 1.99% with bearish technical signals from moving averages. The company reported $120.04M revenue in 2016 with improving net margin (-0.59% vs -4.88% in 2015) and positive operating cash flow of $5.81M. Recent news highlights China's AI competition potentially benefiting tech ETFs like KTEC.
KTEC shows operational improvement but faces profitability challenges with negative net income. The stock's technical weakness and volatile earnings history suggest cautious approach. Upside depends on sustained revenue growth and margin expansion in competitive tech ETF space.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
